Drugs / GP681
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06643156 | Sep 2024 → Jan 2025 | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06678542 | Sep 2024 → Feb 2025 | — | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05789342 | Feb → Sep 2023 | — | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05103241 | Oct → Nov 2021 | — | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04729764 | Aug → Dec 2020 | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06574503 | Dec 2024 → Jul 2027 expected | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06573008 | Nov 2024 → Dec 2025 overdue | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05789342 ↗ |
| Known as | Suraxavir marboxil | “Suraxavir marboxil (GP681) is a prodrug of a novel polymerase acidic protein inhibitor” PMID 41025645 ↗ Sep 20251“Suraxavir Marboxil (GP681) is a prodrug metabolized to GP1707D07” PMID 40291342 ↗ Apr 2025 |
| Route | Oral | “20-80 mg single oral dosing was supported for further clinical development” PMID 41025645 ↗ Sep 2025 |